Welcome to our dedicated page for KAIROS PHARMA SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kairos Pharma SEC filings document regulatory disclosures for a clinical-stage oncology company, including Form 8-K reports on clinical updates for ENV-105 in metastatic castration-resistant prostate cancer and non-small cell lung cancer. The filings also record material agreements tied to oncology asset rights, including license novations involving Cedars-Sinai patents and TRC105/CD105 technology.
Other filings describe proposed oncology asset transactions, executive and director equity compensation under the 2023 Equity Incentive Plan, cash bonus approvals, furnished press releases, and exhibit materials. These records outline governance actions, capital-stock award mechanics, intellectual-property and license arrangements, and event disclosures relevant to Kairos Pharma's development-stage business.
Kairos Pharma, Ltd. has filed a shelf registration statement allowing it to offer up to $75,000,000 of common stock, preferred stock, debt securities, warrants and units over time. Within this, the company established an at‑the‑market equity program to sell up to $4,524,949 of common stock through H.C. Wainwright & Co. on the NYSE American.
Kairos is a clinical‑stage cancer drug developer with no approved products and no product revenue. It reported net losses of $4.1 million for the nine months ended September 30, 2025 and $2.6 million for 2024, with an accumulated deficit of about $12.9 million. As of January 12, 2026, public float was approximately $13,574,846, and the company is subject to limits that cap primary offerings under this registration at one‑third of its public float in any 12‑month period.
The filing details prior financing structures, including a $30 million equity line with Helena and a January 2025 PIPE that issued pre‑funded and common warrants, and explains that future proceeds from this shelf may support research and clinical development, working capital and other general corporate purposes.
Kairos Pharma, Ltd. reported an insider equity grant to its Chief Scientific Officer. On October 8, 2025, the officer acquired 171,756 restricted stock units (RSUs) of common stock at a price of $0.00 per share under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan.
The 171,756 RSUs are scheduled to vest on the first anniversary of the grant date, October 8, 2026. After this grant, the reporting person beneficially owns 1,311,739 shares, consisting of 1,135,317 shares of common stock and 176,422 RSUs that remain subject to vesting, all held as a direct ownership position.
Kairos Pharma, Ltd. director Hyun W. Bae reported equity awards and updated share ownership. On 09/16/2025, 10,000 restricted stock units (RSUs) of common stock were acquired at a price of $0.00, reflecting RSUs granted on September 16, 2024 in conjunction with the company’s initial public offering and scheduled to vest in three annual installments starting on the IPO anniversary. On 10/08/2025, an additional 19,084 RSUs were acquired at $0.00, which are scheduled to vest in full on the first anniversary of their grant date.
After these transactions, Bae beneficially owns 73,370 shares of common stock, consisting of 54,286 shares and 19,084 RSUs that remain subject to vesting, all held directly.
Kairos Pharma, Ltd. (KAPA) reported an equity award to its VP of Research and Development on a Form 4. On 10/08/2025, the officer acquired 152,672 restricted stock units (RSUs) of common stock at a price of $0.00 under the company’s 2023 Equity Incentive Plan. These RSUs are scheduled to vest in full on the first anniversary of the grant date.
Following this grant, the officer beneficially owns 299,529 equity interests, consisting of 142,191 shares of common stock and 157,338 RSUs that remain subject to vesting. The filing indicates the holdings are owned directly.
Kairos Pharma, Ltd. (KAPA) reported equity awards to a director via a Form 4 filing. On 09/16/2025, the director acquired 10,000 shares of common stock at $0.00 per share, representing restricted stock units (RSUs) granted under the company’s 2023 Equity Incentive Plan in connection with its initial public offering. Following this grant, the director beneficially owned 10,000 shares, combining common stock and unvested RSUs.
On 10/08/2025, the director received an additional 19,084 RSUs at $0.00 per share under the same plan, which are scheduled to vest in full on the first anniversary of the grant date. After this transaction, the director beneficially owned 29,084 shares, consisting of 3,334 shares of common stock and 25,750 RSUs that remain subject to vesting.
Kairos Pharma, Ltd. (KAPA) reported an insider equity award on a Form 4. Director Rahul Singhvi received 19,084 restricted stock units (RSUs) of common stock on 10/08/2025 under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. These 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date and were recorded at a price of $0.00, reflecting that this is an equity award, not an open-market purchase.
Following this grant, Singhvi beneficially owns 49,204 RSUs, all of which remain subject to vesting conditions and are reported as directly held. The filing is made by a single reporting person in the capacity of director, and it documents non-derivative equity compensation rather than any sale of shares.
Kairos Pharma (KAPA) reported an equity award to its Chief Financial Officer, Doug Samuelson. On 10/08/2025, he received 152,672 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan at a price of $0.00 per share. These RSUs are scheduled to vest in full on the first anniversary of the grant date.
Following this grant, Samuelson beneficially owns 293,039 common shares and RSUs in total, consisting of 140,367 shares of common stock and 152,672 RSUs that remain subject to vesting, all held in direct ownership.
Kairos Pharma (KAPA) reported an insider equity grant to its CEO and Chairman, John S. Yu, who is also a director and 10% owner. On 10/08/2025, he received 190,840 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan, with all 190,840 RSUs scheduled to vest on the first anniversary of the grant date. Following this award, he directly beneficially owns 230,105 shares of common stock, which consist of 34,599 shares and 195,506 RSUs that remain subject to vesting, and indirectly holds 5,316,572 shares through The Yu Family Trust, where he is trustee. This filing reflects equity-based compensation and confirms his significant ongoing ownership stake.
Kairos Pharma (KAPA) reported Q3 2025 results. The company recorded a net loss of $1.4 million for the quarter and $4.1 million for the nine months ended September 30, 2025, with no revenue reported. Operating expenses rose as development advanced: R&D was $608k in Q3 ($1.6 million year‑to‑date) and G&A was $827k in Q3 ($2.6 million year‑to‑date).
Liquidity improved through 2025 financings. Cash and cash equivalents were $5.6 million and shareholders’ equity was $7.7 million at September 30, 2025. Year‑to‑date financing cash inflows included $3.1 million net from January pre‑funded units and $3.6 million from the equity line of credit. The company expects current cash to fund operations for at least 12 months from the filing date. Common shares outstanding were 20,821,353 as of November 14, 2025. Subsequent events include a $1.143 million Lonza agreement tied to ENV105 Phase 3 manufacturing preparation and new RSU grants for executives and directors.